Chaim Lebovits, BrainStorm CEO

Af­ter rare pub­lic brush­back, FDA again turns away Brain­Stor­m's ALS drug with RTF let­ter

As a cell ther­a­py biotech de­vel­op­ing a new treat­ment for ALS at­tempt­ed to ap­proach the FDA with its ap­pli­ca­tion, it found the agency’s doors slammed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.